BACKGROUND: Studies considering the risk of atherosclerotic disease (AtD) associated with the use of HAART have reported inconsistent results. METHODS: Data on antiretroviral therapy (ART) use, risk factors for cardiovascular disease (CVD), AtD and death from other causes in 18 603 HIV-infected patients from two established cohorts were evaluated. The relative hazards of AtD and death from other causes were calculated using a proportional hazards competing risks framework. The impact of protease inhibitor (PI)-containing, non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing or PI + NNRTI-containing regimens on these outcomes were compared to nucleoside reverse transcriptase inhibitor (NRTI)-only regimens or stopping therapy, adjusting for known CVD risk factors. RESULTS: In 77 480 person-years of follow-up (median duration 3.49 years) there were 318 AtD events including 92 myocardial infarctions and 2044 deaths. Older age, hypertension, diabetes mellitus, having smoked and HIV disease stage were significantly associated with increased risk of AtD. PI- and NNRTI-containing regimens significantly reduced the joint risk of either AtD or death from other causes compared to NRTI-only or stopping therapy [hazard ratio (HR) for PI-containing ART, 0.76, 95% confidence interval (CI), 0.73-0.78, P< 0.001; NNRTI-containing ART, 0.69, 95% CI, 0.65-0.74; P< 0.001). PI-containing ART was associated with a borderline significant increased risk of myocardial infarction (cause-specific HR for PI-containing ART 1.19, 95% CI, 1.01-1.40, P = 0.04) but not with increased risk of AtD compared to NRTI-only regimens or stopping therapy (cause-specific HR for PI-containing ART, 1.03, 95% CI, 0.95-1.13, P = 0.44). CONCLUSIONS: Overall benefits of PI- and NNRTI-based ART in reducing mortality significantly outweigh any risks of AtD in the "short-term" follow-up of this study. Traditional cardiac risk factors play an important role in determining AtD risk status.
BACKGROUND: Studies considering the risk of atherosclerotic disease (AtD) associated with the use of HAART have reported inconsistent results. METHODS: Data on antiretroviral therapy (ART) use, risk factors for cardiovascular disease (CVD), AtD and death from other causes in 18 603 HIV-infectedpatients from two established cohorts were evaluated. The relative hazards of AtD and death from other causes were calculated using a proportional hazards competing risks framework. The impact of protease inhibitor (PI)-containing, non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing or PI + NNRTI-containing regimens on these outcomes were compared to nucleoside reverse transcriptase inhibitor (NRTI)-only regimens or stopping therapy, adjusting for known CVD risk factors. RESULTS: In 77 480 person-years of follow-up (median duration 3.49 years) there were 318 AtD events including 92 myocardial infarctions and 2044 deaths. Older age, hypertension, diabetes mellitus, having smoked and HIV disease stage were significantly associated with increased risk of AtD. PI- and NNRTI-containing regimens significantly reduced the joint risk of either AtD or death from other causes compared to NRTI-only or stopping therapy [hazard ratio (HR) for PI-containing ART, 0.76, 95% confidence interval (CI), 0.73-0.78, P< 0.001; NNRTI-containing ART, 0.69, 95% CI, 0.65-0.74; P< 0.001). PI-containing ART was associated with a borderline significant increased risk of myocardial infarction (cause-specific HR for PI-containing ART 1.19, 95% CI, 1.01-1.40, P = 0.04) but not with increased risk of AtD compared to NRTI-only regimens or stopping therapy (cause-specific HR for PI-containing ART, 1.03, 95% CI, 0.95-1.13, P = 0.44). CONCLUSIONS: Overall benefits of PI- and NNRTI-based ART in reducing mortality significantly outweigh any risks of AtD in the "short-term" follow-up of this study. Traditional cardiac risk factors play an important role in determining AtD risk status.
Authors: Shreya G Rao; Karla I Galaviz; Hawkins C Gay; Jingkai Wei; Wendy S Armstrong; Carlos Del Rio; K M Venkat Narayan; Mohammed K Ali Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Erin Madden; Grace Lee; Donald P Kotler; Christine Wanke; Cora E Lewis; Russell Tracy; Steven Heymsfield; Michael G Shlipak; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld Journal: AIDS Date: 2008-03-30 Impact factor: 4.177
Authors: Stephen Y Xue; Valeria Y Hebert; Danicia M Hayes; Corie N Robinson; Mitzi Glover; Tammy R Dugas Journal: Toxicol Sci Date: 2013-05-02 Impact factor: 4.849
Authors: Marc O Siegel; Alison G Borkowska; Larisa Dubrovsky; Mary Roth; Ruth Welti; Afsoon D Roberts; David M Parenti; Gary L Simon; Dmitri Sviridov; Samuel Simmens; Michael Bukrinsky; Michael L Fitzgerald Journal: Atherosclerosis Date: 2015-08-29 Impact factor: 5.162
Authors: Kerry Townsend; Eric G Meissner; Sreetha Sidharthan; Maureen Sampson; Alan T Remaley; Lydia Tang; Anita Kohli; Anu Osinusi; Henry Masur; Shyam Kottilil Journal: AIDS Res Hum Retroviruses Date: 2015-12-15 Impact factor: 2.205
Authors: Ba Hamadou; Marie Ntep Ngweth; Miriam Megueo Fotso; Liliane Mfeukeu-Kuate; Ahmadou M Jingi; Jean Jacques Noubiap; Chris Nadege Nganou; Jerome Boombhi; Sylvie Ndongo Amougou; Alain Menanga; Samuel Kingue Journal: Cardiovasc Diagn Ther Date: 2017-12
Authors: Line D Rasmussen; Lars H Omland; Court Pedersen; Jan Gerstoft; Gitte Kronborg; Janne Jensen; Niels Obel Journal: BMC Infect Dis Date: 2010-06-14 Impact factor: 3.090
Authors: Laura A Benjamin; Alan Bryer; Hedley C A Emsley; Saye Khoo; Tom Solomon; Myles D Connor Journal: Lancet Neurol Date: 2012-10 Impact factor: 44.182
Authors: Clay Bavinger; Eran Bendavid; Katherine Niehaus; Richard A Olshen; Ingram Olkin; Vandana Sundaram; Nicole Wein; Mark Holodniy; Nanjiang Hou; Douglas K Owens; Manisha Desai Journal: PLoS One Date: 2013-03-26 Impact factor: 3.240